Oasmia is a specialty pharmaceutical company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, in several indications, including cancer.
Non Regulatory April 12, 2021Oasmia Presents Cantrixil Final Phase I Data at the 2021 AACR Annual Meeting
Non Regulatory April 1, 2021Oasmia Pharmaceutical Appoints Dr Reinhard Koenig as Chief Scientific Officer
Non Regulatory March 26, 2021Oasmia to Present Cantrixil Final Phase I Data at the 2021 AACR Virtual Annual Meeting
Oasmia Pharmaceutical published its Year-end report for the shortened financial year May 1, 2020 – December 31, 2020 on February 19, 2021, at 08.00 am CET. The company held a conference call and an online presentation on the same day at 10.00 am CET.